William Blair Issues Positive Outlook for Repligen Earnings

Repligen Co. (NASDAQ:RGEN) – Investment analysts at William Blair lifted their FY2024 earnings per share (EPS) estimates for shares of Repligen in a report released on Wednesday, December 11th. William Blair analyst M. Larew now anticipates that the biotechnology company will post earnings per share of $1.58 for the year, up from their previous estimate of $1.44. The consensus estimate for Repligen’s current full-year earnings is $1.52 per share. William Blair also issued estimates for Repligen’s Q4 2024 earnings at $0.45 EPS, Q1 2025 earnings at $0.38 EPS, Q2 2025 earnings at $0.46 EPS, Q3 2025 earnings at $0.45 EPS and Q4 2025 earnings at $0.50 EPS.

A number of other research firms have also recently commented on RGEN. Royal Bank of Canada restated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Wells Fargo & Company initiated coverage on Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. Finally, StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Price Performance

Shares of RGEN opened at $156.41 on Friday. The business’s 50-day moving average is $142.66 and its two-hundred day moving average is $141.77. The company has a market capitalization of $8.76 billion, a P/E ratio of -422.72, a P/E/G ratio of 4.67 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $211.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the firm earned $0.23 EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Toronto Dominion Bank lifted its stake in Repligen by 1.5% in the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 75 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Repligen by 1.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock worth $982,000 after purchasing an additional 89 shares in the last quarter. MML Investors Services LLC lifted its stake in Repligen by 2.7% in the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock worth $503,000 after purchasing an additional 89 shares in the last quarter. Ballentine Partners LLC lifted its stake in Repligen by 6.2% in the 3rd quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 105 shares in the last quarter. Finally, Diversified Trust Co lifted its stake in Repligen by 3.7% in the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock worth $372,000 after purchasing an additional 106 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.